NCT00461630View on ClinicalTrials.gov

Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE

PHASE3CompletedINTERVENTIONAL
Enrollment

25,673

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Cardiovascular DiseasePeripheral Arterial DiseaseDiabetes MellitusCoronary Heart Disease
Interventions
DRUG

ER niacin/laropiprant

DRUG

simvastatin

40 mg simvastatin tablet orally per day as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level

DRUG

ezetimibe/simvastatin

10 mg ezetimibe plus 40 mg simvastatin in single tablet taken once daily as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level

Trial Locations (1)

OX3 7LF

Clinical Trial Service Unit, University of Oxford, Oxford

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Oxford

OTHER

NCT00461630 - Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE | Biotech Hunter | Biotech Hunter